NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

Adherence to Medication

2005 • 7,581 citations

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

2002 • 4,254 citations

Can Treatment Adherence Be Improved by Using Rubin's Four Tendencies Framework to Understand a Patient's Response to Expectations

2017 • 3,779 citations

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

1996 • 3,649 citations

Diagnosis of gastrointestinal stromal tumors: A consensus approach

2002 • 3,361 citations

Two Hundred Gastrointestinal Stromal Tumors

2000 • 2,510 citations

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 • 2,500 citations

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

2003 • 2,224 citations

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

2003 • 2,216 citations

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

2001 • 2,038 citations

Gastrointestinal stromal tumors: Pathology and prognosis at different sites

2006 • 1,902 citations

Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

2001 • 1,849 citations

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

1999 • 1,653 citations

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 • 1,629 citations

Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

2007 • 1,438 citations

Gastrointestinal Stromal Tumors: Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis

2006 • 1,404 citations

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

2009 • 1,294 citations

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

2001 • 1,267 citations

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

2000 • 1,264 citations

Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era

2005 • 1,251 citations

Gastrointestinal Stromal Tumors of the Stomach

2004 • 1,212 citations

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

2006 • 1,126 citations

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

2000 • 1,038 citations

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

2007 • 1,033 citations

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 • 1,027 citations

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

2001 • 964 citations

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

2008 • 958 citations

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 • 862 citations

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

2005 • 809 citations

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

2005 • 805 citations

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

2006 • 793 citations

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

2008 • 726 citations

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

2001 • 698 citations

SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma

2009 • 686 citations

The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000

2005 • 672 citations

Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors

2003 • 665 citations

The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status

2004 • 645 citations

Gastrointestinal Stromal Tumors of the Jejunum and Ileum

2006 • 630 citations

Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT)

2000 • 620 citations

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

2009 • 602 citations

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

2008 • 596 citations

Molecular characterisation of soft tissue tumours: a gene expression study

2002 • 581 citations

Lymph Node Metastasis From Soft Tissue Sarcoma in Adults Analysis of Data From a Prospective Database of 1772 Sarcoma Patients

1993 • 565 citations

We Should Desist Using RECIST, at Least in GIST

2007 • 543 citations

Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome

2000 • 528 citations

KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation

2005 • 518 citations

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)

2007 • 496 citations

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

2005 • 491 citations

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

2009 • 490 citations

KIT-Negative Gastrointestinal Stromal Tumors

2004 • 478 citations

Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies

2006 • 467 citations

Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD

2007 • 466 citations

KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size

2002 • 445 citations

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

2010 • 441 citations

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

2004 • 439 citations

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

2008 • 435 citations

Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors

2006 • 434 citations

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

2009 • 426 citations

Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors

2002 • 422 citations

A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors

2008 • 422 citations

Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and Staging

1992 • 420 citations

DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors

2009 • 416 citations

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

2008 • 406 citations

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

2008 • 404 citations

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

2003 • 399 citations

Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors

2006 • 393 citations

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

2006 • 389 citations

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

2007 • 386 citations

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)

2007 • 385 citations

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

2009 • 381 citations

Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations

2006 • 370 citations

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg

2005 • 369 citations

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

2009 • 365 citations

Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors

2008 • 364 citations

Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification study

2005 • 359 citations

Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

2006 • 355 citations

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.

2003 • 355 citations

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

2009 • 355 citations

High incidence of microscopic gastrointestinal stromal tumors in the stomach

2006 • 354 citations

Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)

2005 • 342 citations

A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

2004 • 338 citations

Management of hypertension in angiogenesis inhibitor-treated patients

2009 • 333 citations

Biological and clinical review of stromal tumors in the gastrointestinal tract.

2000 • 319 citations

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

2008 • 308 citations

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

2004 • 305 citations

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

2006 • 303 citations

Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults

2005 • 303 citations

Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor

2007 • 303 citations

Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study

2005 • 297 citations

The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney–Stratakis syndrome): molecular genetics and clinical implications

2009 • 288 citations

Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes

2009 • 276 citations

Analysis of Prognostic Factors

1987 • 271 citations

Leiomyosarcoma of the small and large bowel

1978 • 269 citations

Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib

2006 • 263 citations

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)

2002 • 261 citations

Gastrointestinal Stromal Tumors in Children and Young Adults

2005 • 258 citations

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

2008 • 248 citations

Corticosteroids can reverse severe imatinib-induced hepatotoxicity.

2006 • 246 citations

Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors

2008 • 245 citations

Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST

2007 • 239 citations

Gastrointestinal Stromal Tumors With KIT Exon 11 Deletions Are Associated With Poor Prognosis

2006 • 234 citations

Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases

2006 • 220 citations

Gastrointestinal stromal tumor: 5 years later

2005 • 220 citations

Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics

2003 • 219 citations

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

2004 • 215 citations

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

2005 • 204 citations

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

2009 • 198 citations

Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site

2004 • 195 citations

Gastrointestinal cancer

1995 • 193 citations

Task Force Report

2006 • 190 citations

Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors

2006 • 189 citations

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

2006 • 188 citations

Indications for Imatinib Mesylate Therapy and Clinical Management

2004 • 187 citations

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases

2008 • 179 citations

Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver

2006 • 179 citations

A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

2008 • 175 citations

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

2005 • 170 citations

CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor

2007 • 170 citations

Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1

2008 • 170 citations

Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection

2006 • 163 citations

Pediatric KIT–Wild-Type and Platelet-Derived Growth Factor Receptor α–Wild-Type Gastrointestinal Stromal Tumors Share KIT Activation but not Mechanisms of Genetic Progression with Adult Gastrointestinal Stromal Tumors

2007 • 162 citations

Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era

2006 • 161 citations

Early Prediction of Response to Sunitinib After Imatinib Failure by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor

2008 • 157 citations

Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate

2005 • 156 citations

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

2006 • 155 citations

Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors

2004 • 154 citations

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

2009 • 152 citations

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

2009 • 150 citations

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

2009 • 147 citations

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

2009 • 147 citations

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

2004 • 146 citations

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients

2003 • 145 citations

A guide for the diagnosis and management of gastrointestinal stromal cell tumors

2009 • 143 citations

GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology

2005 • 140 citations

Expression of c‐kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours

1999 • 134 citations

Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

2003 • 131 citations

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

2007 • 128 citations

Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas

2002 • 128 citations

Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs)

2004 • 125 citations

A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas

2003 • 121 citations

Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors

2005 • 118 citations

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

2008 • 118 citations

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

2008 • 115 citations

Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial

2009 • 111 citations

Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course

2003 • 110 citations

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

2009 • 108 citations

Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib

2004 • 107 citations

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

2009 • 100 citations

Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model

2005 • 99 citations

GI stromal tumors

2003 • 93 citations

Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis

2009 • 91 citations

Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium

2008 • 90 citations

Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases

2009 • 88 citations

Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance

2009 • 84 citations

Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of Northern Norway

2006 • 80 citations

Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients

2008 • 80 citations

Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain

2006 • 80 citations

Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens

2008 • 79 citations

Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor

2007 • 75 citations

Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

2008 • 74 citations

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate

2009 • 74 citations

Laparoscopic Gastric Gastrointestinal Stromal Tumor Resection

2008 • 73 citations

Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate

2009 • 72 citations

State-of-the Art Therapy for Gastrointestinal Stromal Tumors

2005 • 72 citations

PDGFR expression in differential diagnosis between KIT‐negative gastrointestinal stromal tumours and other primary soft‐tissue tumours of the gastrointestinal tract

2005 • 72 citations

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)

2008 • 71 citations

Endoscopic band ligation of small gastric stromal tumors and follow-up by endoscopic ultrasonography

2006 • 71 citations

Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors

2006 • 69 citations

Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target

2009 • 67 citations

Treatment of metastatic sarcoma to the liver with bland embolization

2006 • 67 citations

Laparoscopic resection for gastrointestinal stromal tumors of the stomach

2008 • 63 citations

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)

2009 • 55 citations

A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors

2002 • 55 citations

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning

2004 • 52 citations

Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models

2006 • 51 citations

Inherited Predisposition to Gastrointestinal Stromal Tumor

2009 • 49 citations

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

2008 • 45 citations

PKCθ expression in gastrointestinal stromal tumor

2006 • 45 citations

Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria.

2009 • 43 citations

Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment

2009 • 39 citations

Small and microscopically detected gastrointestinal stromal tumours: an overview

2007 • 39 citations

PDGFRA Immunostaining Can Help in the Diagnosis of Gastrointestinal Stromal Tumors

2008 • 36 citations

Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis

2009 • 35 citations

The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors

2008 • 34 citations

Strong PDGFRA Positivity Is Seen in GISTs But Not in Other Intra-abdominal Mesenchymal Tumors: Immunohistochemical and Mutational Analyses

2006 • 33 citations

Correlation of immunophenotype with progression‐free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate

2006 • 32 citations

Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST)

2009 • 31 citations

Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours

2004 • 28 citations

Diagnosis and treatment of gastrointestinal stromal tumors

2010 • 26 citations

Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)

2009 • 26 citations

Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST

2007 • 26 citations

Comments and Suggestions

1929 • 23 citations

Gastrointestinal Stromal Tumor: Role of Interventional Radiology in Diagnosis and Treatment

2009 • 22 citations

Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: Analysis from a single-center contrast study

2009 • 10 citations

Time to secondary resistance (TSR) after interruption of imatinib: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival

2009 • 9 citations